• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    New therapeutic agents in ovarian cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Collinson, Fiona J
    Jayson, Gordon C
    Affiliation
    University of Leeds, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.uk
    Issue Date
    2009-02
    
    Metadata
    Show full item record
    Abstract
    PURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
    Citation
    New therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.
    Journal
    Current Opinion in Obstetrics & Gynecology
    URI
    http://hdl.handle.net/10541/74033
    DOI
    10.1097/GCO.0b013e32831ffe71
    PubMed ID
    19125003
    Type
    Article
    Book
    Language
    en
    ISSN
    1473-656X
    ae974a485f413a2113503eed53cd6c53
    10.1097/GCO.0b013e32831ffe71
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research
    Medical Oncology

    entitlement

    Related articles

    • Targeted agents in ovarian cancer.
    • Authors: Kristedja TS, Morgan RJ, Cristea M
    • Issue date: 2010 Sep
    • Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    • Authors: Dhillon S
    • Issue date: 2013 Aug
    • Angiogenesis inhibitors for the treatment of ovarian cancer.
    • Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
    • Issue date: 2011 Sep 7
    • New drugs for ovarian cancer.
    • Authors: Kaye SB
    • Issue date: 2008 Feb
    • Bevacizumab in the treatment of ovarian cancer.
    • Authors: Han ES, Monk BJ
    • Issue date: 2007 Oct
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.